Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1804 Target Snapshot

Somatostatin receptor type 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,599Compounds
160Assays
4Approved Drugs
2,117.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Somatostatin receptor type 2 shows approved-linked disease relevance led by acromegaly. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P30874. Start with acromegaly, then reuse UniProt P30874 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acromegaly, then reuse UniProt P30874 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 5 linked drugs
Open source guide
Disease program
acromegaly

Somatostatin receptor type 2 shows approved-linked disease relevance led by acromegaly. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with acromegaly because it currently carries approved-linked support. Linked drugs include LANREOTIDE ACETATE, PALTUSOTINE, PASIREOTIDE DIASPARTATE, PASIREOTIDE PAMOATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Somatostatin receptor type 2 as ChEMBL target CHEMBL1804, mapped to UniProt P30874. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Somatostatin receptor type 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1804
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P30874
Somatostatin receptor type 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Somatostatin receptor type 2 is the right protein anchor across sources, using UniProt P30874 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acromegaly is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSomatostatin receptor type 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP30874
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSomatostatin receptor type 2
UniProt AccessionP30874
Component TypeProtein
Sequence Length369 aa

Somatostatin receptor type 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Somatostatin receptor type 2, mapped to UniProt P30874. Sequence length is 369 aa.

Mapped IDP30874
Review nameSomatostatin receptor type 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Somatostatin receptor type 2 shows approved-linked disease relevance led by acromegaly. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
acromegaly
5 linked drugs · 5 direct · 5 efficacy
Linked drugLANREOTIDE ACETATE
Linked drugPALTUSOTINE
Linked drugPASIREOTIDE DIASPARTATE
Linked drugPASIREOTIDE PAMOATE
Approved-linked Approved
carcinoid syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugLANREOTIDE ACETATE
Linked drugPALTUSOTINE
Approved-linked Approved
pituitary-dependent Cushing's disease
1 linked drug · 1 direct · 1 efficacy
Linked drugPASIREOTIDE DIASPARTATE
Late clinical Phase III
post-operative sign or symptom
1 linked drug · 1 direct · 1 efficacy
Linked drugVAPREOTIDE
Clinical signal Phase II
Hypoglycemia
1 linked drug · 1 direct · 1 efficacy
Linked drugPASIREOTIDE DIASPARTATE
Clinical signal Phase II
Pituitary Gland Adenoma
1 linked drug · 1 direct · 1 efficacy
Linked drugONZIGOLIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with acromegaly because it currently carries approved-linked support. Linked drugs include LANREOTIDE ACETATE, PALTUSOTINE, PASIREOTIDE DIASPARTATE, PASIREOTIDE PAMOATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacromegaly
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
6
Phase III
3
Phase II
Assay Mix

Activity Type Distribution

IC50564.0
KI679.0
EC50838.0
KD36.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL99895 11.0 Ki 0.01 Preclinical
CHEMBL4590517 10.89 Ki 0.013 Preclinical
CHEMBL4861425 10.89 EC50 0.013 Preclinical
CHEMBL4866325 10.89 EC50 0.013 Preclinical
CHEMBL4872591 10.89 EC50 0.013 Preclinical
CHEMBL4849848 10.85 EC50 0.014 Preclinical
CHEMBL4541310 10.82 Ki 0.015 Preclinical
CHEMBL4550617 10.82 Ki 0.015 Preclinical
CHEMBL4584764 10.82 Ki 0.015 Preclinical
CHEMBL4860633 10.82 EC50 0.015 Preclinical
Distribution

pChEMBL Value Distribution

78
5.0
42
5.5
124
6.0
98
6.5
217
7.0
124
7.5
131
8.0
125
8.5
112
9.0
78
9.5
pChEMBL
Approved Drugs

Approved Drugs

PASIREOTIDE
CHEMBL3349607
Approved 2012
Properties Compare Identifier
LANREOTIDE
CHEMBL1201185
Approved 2007
Properties Compare Identifier
OCTREOTIDE
CHEMBL1680
Approved 1988
Properties Compare Identifier
Assay Landscape

Assay Landscape

161
Total Assays
936
Tested Compounds
3
Assay Types
Binding — 133 assays, 936 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 63 349 7.3
cell-based format 53 398 8.0
assay format 14 118 6.8
cell membrane format 2 22 5.5
cell-free format 1 49 9.6
Functional — 26 assays, 118 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 23 116 8.3
single protein format 2 0 —
assay format 1 2 6.5
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine